- BBI Solutions has successfully acquired IBEX Technologies, enhancing its capabilities in the In Vitro Diagnostic (IVD) market.
- The acquisition strategically positions BBI to meet the growing global demand for IVD haemostasis testing.
- The partnership promises mutual benefits for customers and employees, with all IBEX staff transitioning to BBI.
BBI Solutions, a manufacturer of immunodiagnostic reagents, has announced the successful acquisition of IBEX Technologies, a developer and manufacturer of high-precision enzymes and diagnostic solutions based in Montréal, Québec. The acquisition, effective from 8th April 2024.
The acquisition is driven by an ageing population, the rising prevalence of chronic diseases, and an increased reliance on point-of-care tests in surgery and trauma settings. By incorporating IBEX’s innovative enzyme technologies into its extensive portfolio of recombinant proteins, BBI is also responding to the industry shift towards recombinantly produced reagents for IVD tests, reflecting a preference for more standardized and reliable testing methodologies.
Mario Gualano, Chief Executive Officer of BBI, expressed his excitement about the acquisition, stating, “We are thrilled to welcome IBEX’s talented team to BBI and to incorporate their innovative enzymes into our rapidly expanding recombinant protein portfolio. It also marks a further milestone in our mission to be a crucial ally for IVD manufacturers worldwide by offering an extensive portfolio of critical raw materials, unparalleled expertise, and comprehensive support at every stage of assay development.”
The acquisition promises mutual benefits for customers and employees alike. All IBEX staff will transition to BBI, enjoying the benefits of being part of a renowned multinational organization, while customers can expect continued service excellence without interruption. This partnership is set to offer significant strategic advantages, including a more diversified offering for IVD customers and a reinforced position in the diagnostic enzymes market.
In light of the successful closing of the transaction, IBEX has applied for delisting from the TSX Venture Exchange, which is expected to occur on or about Thursday, April 11, 2024. This move, supported by BBI’s strong distribution and manufacturing framework, lays a robust foundation for further growth and enhanced service capabilities across the globe.
Stay ahead of trends and best practices
